370
Participants
Start Date
November 30, 2021
Primary Completion Date
January 14, 2027
Study Completion Date
January 14, 2027
REGN4336
Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
Cemiplimab
Administered concomitantly every 3 weeks (Q3W) by IV infusion
REGN5678
Administered concomitantly QW by IV infusion
Sarilumab
Administered once by IV infusion as prophylaxis prior to REGN4336 IV
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
Penn Medicine University of Pennsylvania Health System, Philadelphia
RECRUITING
Thomas Jefferson University Hospital, Philadelphia
WITHDRAWN
Fox Chase Cancer Center, Philadelphia
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
University of Maryland Greenebaum Cancer Center, Baltimore
RECRUITING
Atrium Health Levine Cancer Institute, Charlotte
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
The Ohio State University James Cancer Hospital, Columbus
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Stanford University Medical Center - Blake Wilbur Drive, Palo Alto
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
Regeneron Pharmaceuticals
INDUSTRY